Mapi is the leading Patient-Centered Research company serving academia, life science researchers, and the pharmaceutical industry for over 40 years. Mapi’s commitment to patient-focused research is demonstrated not only by our expertise and nearly four decades of service but also through our direct contribution back to the industry. Mapi is among only a handful of global organizations that is capable of engaging with a patients’ complete ecosystem, their HCPs, Patient Communities, payers, and even regulators. And only Mapi has the unique history to make us the most experienced at interacting with all of them.
The Mapi Group offers strategic consulting in Market Access and Health Economics & Outcomes Research, Global Late Phase Research, Linguistic Validation services and is supported by Mapi Research Trust’s unique information resources in the field of Patient Centered Outcomes. We reach 130 countries around the globe.
A value promise, as well as a value proposition, has to be translated into a financial value. Sound and accurate market access considerations need to be made when the sales potential of an in-house or licensed asset has been assessed. We assist your business development, market analytics, and marketing teams in factoring market access hurdles in their sales forecasting models. This improves the robustness of the assumptions made on the new technology adoption, and its speed, which ultimately increases the reliability of the Net Present Value estimate.
To meet the increasing demand of health care decision makers for compelling evidence that supports the value of your product, you need high quality scientific services. That’s exactly what the Mapi HEOR team can provide.
Our scientists and researchers have established themselves at the forefront of patient centered outcomes, evidence synthesis and health economic evaluations, gaining respect from academic, industry and regulatory players for the past 20 years.
In today’s world, any new health technology that is aimed at addressing a specific disease condition must factor the payers' expectations and requirements into its research program from its earliest stages. Mapi helps support your research and development teams, as well as your market access organization, to take these factors into consideration and determine which key product and market attributes will be needed to ensure the launch of a differentiated product that will meet the payers' approval.
To de-risk a program in pre-launch, the following requirements should be addressed:
Mapi helps enable commercialization throughout the product lifecycle with our Real World Strategy & Analytics offerings.We provide guidance that’s unmatched in the industry by combining our expertise in strategic consulting, market access, evidence synthesis, health economics, and outcomes services. We work with you to identify and communicate key values of every treatment, and help ensure that the right medicine is available to the right patients.
The RWS&A group is home to industry-leading experts in establishing evidence development and dissemination strategy, where services support an integrated outcomes strategy encompassing safety, effectiveness, and economic endpoints.
Mapi has a deep understanding of every integral part of the evidence development process: from payers, HTA agencies, and regulators to benefit-risk and the patient voice.
We use that understanding to help you develop a robust strategy that identifies the evidence required for all key stakeholders and supports authorisation/approval and reimbursement decision-making. We specialize in developing and supporting strategies that address the unique challenges facing market access for specialty products and rare diseases, where communicating benefit-risk and the patient voice is crucial to successful market access.
At Mapi, we have industry-leading experience in the market access challenges that our clients face. Our multidisciplinary team gathers insights from stakeholders and transforms them into strategies that can guide access decision-making throughout the product life cycle. We develop evidence dissemination messaging that ensures early evidence generation supports the value story and market access strategy. These communications include dossiers, publications, training slide sets, local market access support, and more.
Mapi RSW&A can help you realize the potential of real world data (retrospective, prospective) and analytics, utilizing research conducted outside of a controlled clinical environment to generate valuable insights that support your products. Our team utilizes advanced statistical methods applicable to the analysis of real-world data. Our Systematic Literature Reviews collect and critically analyze multiple research studies or papers, while our expert meta-analyses synthesize data across multiple studies. Finally, Mapi develops and employs innovative technologies that provide unprecedented access to data for our customers.
We have extensive experience in developing models to support your economic value proposition. We work with you to understand your needs before delivering bespoke cost-effectiveness, resource utilization, and budget impact models that deliver the metrics needed to demonstrate the health economic value of their product.
Mapi is a pioneer in patient-reported outcomes, and we partner with customers around the world to create tailor-made solutions that measure a wide range of factors, including: comparative effectiveness, comparative safety and benefit-risk, disease burden/unmet need, risk minimization strategy effectiveness, drug utilization, and many more.
Following the most recent guidelines of HTA agencies, Mapi has performed over 150 SLRs in a variety of therapeutic categories and submitted in over 20 countries. These have been accomplished as stand-alone projects, as part of the development of indirect treatment comparisons and cost-effectiveness models, and for reimbursement dossiers and value dossiers.
Systematic reviews are not limited to the synthesis of efficacy and safety evidence of medical interventions, but can also address cost-effectiveness evaluations, epidemiology, burden of illness and cost-of-illness, and Patient-Reported Outcomes studies.
As part of our dedication to HEOR, Mapi experts stay up-to-date with the latest trends and developments in SLRs:
Mapi USA Inc has not received any reviews.
Mapi USA Inc has not received any endorsements.